‘Like Christmas’: woman’s relief after test finds she can skip chemotherapy
A groundbreaking genomic test has shown that many women with breast cancer can safely skip chemotherapy. The trial results indicate a high five-year cancer-free survival rate for those who avoided chemotherapy, comparable to those who underwent the treatment. Karen Bonham, a participant in the trial, expressed immense relief upon learning she could forgo chemotherapy and is now cancer-free after nearly nine years.
- ▪The Optima trial involved 4,429 breast cancer patients from multiple countries.
- ▪The genomic test analyzes 50 specific genes to determine the necessity of chemotherapy.
- ▪The five-year cancer-free survival rate was 93.7% for those who skipped chemotherapy.
The Guardian — Science publishes from United Kingdom and files mainly under science. We currently carry 155 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Guardian — Science |
| Canonical URL | https://www.theguardian.com/society/2026/may/29/breast-cancer-chemotherapy-genomic-test-case-study |
| Publication time | Fri, 29 May 2026 19:00:57 GMT |
| Retrieval time | 2026-05-29T19:15:02.726Z |
| Last seen | 2026-05-29T19:15:02.726Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 7lTeybG4R-mn |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Dreading chemotherapy, Karen Bonham agreed to join the Optima trial after undergoing surgery. Photograph: SuppliedDreading chemotherapy, Karen Bonham agreed to join the Optima trial after undergoing surgery. Photograph: SuppliedBreast cancer‘Like Christmas’: woman’s relief after test finds she can skip chemotherapy Karen Bonham was part of successful trial for genomic test that determines which women with breast cancer can safely avoid chemotherapy Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy Andrew Gregory Health editorFri 29 May 2026 15.00 EDTSharePrefer the Guardian on GoogleA landmark study shows millions of women with breast cancer could skip chemotherapy thanks to a genomic test that determines who needs the treatment and who doesn’t.The…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Guardian — Science.